Development of T-cell engagers selective for cells co-expressing two antigens

References

• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews, Drug Discovery. 2019;18:1–10.
   PubMed Web of Science ®Google Scholar
• Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B. Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017;8:1850. doi:10.3389/fimmu.2017.01850.
   PubMed Web of Science ®Google Scholar
• Argilés G, Saro J, Segal NH, Melero I, Ros W, Marabelle A, Rodriguez ME, Albanell J, Calvo E, Moreno V, et al. LBA-004 Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2017;28:iii151. doi:10.1093/annonc/mdx302.003.
   Web of Science ®Google Scholar
• Wermke M, Alt J, Kauh J, Back J, Salhi Y, Reddy V, Barve M, Ochsenreither S. 1147PPreliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers. Ann Oncol. 2018;29:viii408–9. doi:10.1093/annonc/mdy288.020.
   Web of Science ®Google Scholar
• Kebenko M, Goebeler M-E, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, Friedrich M, et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. OncoImmunology. 2018;7(8):e1450710.
   PubMed Web of Science ®Google Scholar
• Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018;10(463):eaat5775. doi:10.1126/scitranslmed.aat5775.
   PubMed Web of Science ®Google Scholar
• Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22(13):3286–97. doi:10.1158/1078-0432.CCR-15-1696.
   PubMed Web of Science ®Google Scholar
• Nisthal A, Lee S-H, Kim YK, Bonzon C, Rashid R, Avery KN, Bogaert L, Ardila C, Leung IW, Rodriguez N, et al. Abstract 2286: xmAb30819, an XmAb ® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies. Immunology. 2020;80:2286–2286.
   Google Scholar
• Boustany LM, Wong L, White CW, Diep L, Huang Y, Liu S, Richardson JH, Kavanaugh WM, Irving BA. Abstract A164: EGFR-CD3 bispecific ProbodyTM therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies. Molecular Cancer Therapeutics. 2018:17:A164–A164.
   Web of Science ®Google Scholar
• Cugnetti APG, Liu H, Wang J, Xing C, Wheeler C, Lucas M, Chang C, Frey G, Boyle WJ, Short JM. Abstract 5698: novel conditionally active bispecific T cell engagers targeting solid tumors. Cancer Chem. 2018;2020:5698–5698.
   Google Scholar
• Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, et al. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun. pp.1–10. 2019. doi:10.1038/s41467-018-07882-8
   PubMed Web of Science ®Google Scholar
• Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye X, et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med. 2020;12(525):eaaw7888. doi:10.1126/scitranslmed.aaw7888.
   PubMed Web of Science ®Google Scholar
• Leong SR, Liang W-C, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T, et al. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Mol Pharm. 2015;12(6):1717–29. doi:10.1021/mp5007745.
   PubMedGoogle Scholar
• Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, et al. An antibody-drug conjugate directed against lymphocyte antigen 6 complex, locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies. Clin Cancer Res. 2015;21(14):3252–62. doi:10.1158/1078-0432.CCR-15-0156.
   PubMed Web of Science ®Google Scholar
• Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler NsJr., Powell, Djp DJ. Tumor regression and delayed onset toxicity following B7-H4 CAR T cell therapy. Mol Ther. 2016;24(11):1987–99. doi:10.1038/mt.2016.149.
   PubMed Web of Science ®Google Scholar
• Chuh JDC, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, Sun Y, Lin Z, Schneider K, Zhang P, et al. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response. Mabs. 2020;13(1):1862452. doi:10.1080/19420862.2020.1862452.
   Web of Science ®Google Scholar
• Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, et al. Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17(4):776–85. doi:10.1158/1535-7163.MCT-17-0657.
   PubMed Web of Science ®Google Scholar
• Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, et al. An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood. 2017;129(5):609–18. doi:10.1182/blood-2016-08-735365.
   PubMed Web of Science ®Google Scholar
• Andersen PS, Geisler C, Buus S, Mariuzza RA, Karjalainen K. Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens*. J Biol Chem. 2001;276(36):33452–57. doi:10.1074/jbc.M103750200.
   PubMed Web of Science ®Google Scholar
• Ridgway JBB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody C H 3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9(7):617–21. doi:10.1093/protein/9.7.617.
   Google Scholar
• Atwell S, Ridgway JBB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library11Edited by P.E.wright. J Mol Biol. 1997;270(1):26–35. doi:10.1006/jmbi.1997.1116.
   PubMed Web of Science ®Google Scholar
• Rijn RSV, Simonetti ER, Hagenbeek A, Hogenes MCH, Weger RAD, Dijk MRC, Weijer K, Spits H, Storm G, Bloois LV, et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γc-/- double-mutant mice. Blood. 2003;102(7):2522–31. doi:10.1182/blood-2002-10-3241.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods [Internet] [accessed 2022 Aug 31]. 2019;154:102–17. Available from https://reader.elsevier.com/reader/sd/pii/S104620231830121X?token=951F0C894A5665B52048BCFFA711B119048F561AA95ACDD3CC157A4264B05D01A472B9B5F0340EA1446F651080257A5F.
   Google Scholar
• Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med. 1998;188(12):2381–86. doi:10.1084/jem.188.12.2381.
   PubMed Web of Science ®Google Scholar
• Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25(2):523–33. doi:10.1016/j.ymthe.2016.11.006.
   PubMed Web of Science ®Google Scholar
• Cauwels A, Lint SV, Garcin G, Bultinck J, Paul F, Gerlo S, Heyden JVD, Bordat Y, Catteeuw D, Cauwer LD, et al. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology. 2018;7:e1398876.
   PubMed Web of Science ®Google Scholar
• Cauwels A, Lint SV, Paul F, Garcin G, Koker SD, Parys AV, Wueest T, Gerlo S, Heyden JVD, Bordat Y, et al. Delivering Type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Cancer Res. 2018;78(2):463–74. doi:10.1158/0008-5472.CAN-17-1980.
   PubMed Web of Science ®Google Scholar
• Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered 4-1BBL fusion protein with “activity on demand. Proc National Acad. 2020;117:e1398876.
   Web of Science ®Google Scholar
• Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, Wu H, Dall’Acqua WF. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep. 2017;7(1):40098. doi:10.1038/srep40098.
   PubMedGoogle Scholar
• Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall’Acqua WF. Insights into the molecular basis of a bispecific antibody’s target selectivity. mAbs. 2015;7(3):461–69. doi:10.1080/19420862.2015.1022695.
   PubMed Web of Science ®Google Scholar
• Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34–44. doi:10.4132/jptm.2019.11.03.
   PubMed Web of Science ®Google Scholar
• Godbersen-Palmer C, Coupet TA, Grada Z, Zhang SC, Sentman CL. Toxicity induced by a bispecific T cell–redirecting protein is mediated by both T cells and myeloid cells in immunocompetent mice. J Immunol. 2020;204(11):2973–83. doi:10.4049/jimmunol.1901401.
   PubMed Web of Science ®Google Scholar
• Hosseini I, Gadkar K, Stefanich E, Li -C-C, Sun LL, Chu Y-W, Ramanujan S. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. Npj Syst Biology Appl. 2020;6(1):28. doi:10.1038/s41540-020-00145-7.
   PubMed Web of Science ®Google Scholar
• Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383–95. doi:10.1016/j.ccell.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D, Junttila TT, Han G, Sandoval W, Ovacik MA, et al. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. mAbs. 2016;9(2):213–30. doi:10.1080/19420862.2016.1267089.
   PubMed Web of Science ®Google Scholar
• Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs. 2014;5(1):896–903. doi:10.4161/mabs.26436.
   Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang N-Y, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol. 2013;31(8):753–58. doi:10.1038/nbt.2621.
   PubMed Web of Science ®Google Scholar
• Yin Y, Han G, Zhou J, Dillon M, McCarty L, Gavino L, Ellerman D, Spiess C, Sandoval W, Carter PJ. Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry. Mabs. 2016;8(8):00–00. doi:10.1080/19420862.2016.1232217.
   Web of Science ®Google Scholar
• Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang B-E, Li Y, Mathieu M, Li G, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74(19):5561–71. doi:10.1158/0008-5472.CAN-13-3622-T.
   PubMed Web of Science ®Google Scholar